Table 3.
Covariate | Univariate analyses | Multivariate analyses | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P‐Value | HR | 95% CI | P‐Value | |
NCCN‐IPI risk groups | – | – | 0.000 | – | – | – |
Low | – | – | – | – | – | – |
Low‐intermediate | 1.79 | 0.21, 15.36 | 0.59 | – | – | – |
High‐intermediate | 5.72 | 0.73, 45.2 | 0.098 | – | – | – |
High | 17.49 | 2.17, 140.99 | 0.007 | – | – | – |
TMTV0 (>80.74) | 10.32 | 2.42, 44.084 | 0.002 | – | – | – |
TLG0 (>1036.61) | 10.39 | 2.43, 44.39 | 0.002 | 10.42 | 2.35, 46.30 | 0.002 |
TMTV1 (>4.32) | 6.93 | 2.97, 16.17 | 0.000 | – | – | – |
TLG1 (>14.07) | 6.25 | 2.68, 14.56 | 0.000 | 2.39 | 0.93, 6.16 | 0.072 |
%ΔSUVmax (<86.02) | 5.60 | 1.66, 18.88 | 0.005 | 4.86 | 1.27, 18.54 | 0.021 |
CI, confidence interval; HR, hazards ratio; MTV, metabolic tumor volume; NCCN‐IPI, National Comprehensive Cancer Network International Prognostic Index; PFS, progression‐free survival; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis. The subscripts 0 and 1 represent baseline and interim measures, respectively. The MTV variables were not included in the multivariate model owing to their correlation with the TLG variables.